Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Department of Nursing and Institute of Biomedicine of Salamanca, Neurosciences Area, University Hospital of Salamanca, Salamanca, Spain; 2Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain; 3Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
Список исп. литературыСкрыть список
1. Quinn C, Happell B. Talking about sexuality with consumers of mental health services. Perspect Psychiatr Care 2013;49:13-20.
2. Adam RL, Sidi H, Midin M et al. The role of atypical antipsychotics in sexuality: road to recovery in schizophrenia. Curr Drug Targets (in press).
3. de Jager J, McCann E. Psychosis as a barrier to the expression of sexuality and intimacy: an environmental risk? Schizophr Bull (in press).
4. Simiyon M, Chandra PS, Desai G. Sexual dysfunction among women with schizophrenia. A cross sectional study from India. Asian J Psychiatry 2016;24:93-8.
5. Hou CL, Zang Y, Rosen RC et al. Sexual dysfunction and its impact on quality of life in Chinese patients with schizophrenia treated in primary care. Compr Psychiatry 2016;65:116-21.
6. Lee JY, Kim SW, Lee YH et al. Factors associated with self-rated sexual function in Korean patients with schizophrenia receiving risperidone monotherapy. Hum Psychopharmacol 2015;30:416-24.
7. Montejo AL, Majadas S, Montejo L. Sexual and relational dysfunctions in people with schizophrenia. Eur Psychiatry 2014;29(Suppl. 1):1.
8. Gonzalez-Torres MA, Salazar MA, Inchausti L et al. Lifetime sexual behavior of psychiatric inpatients. J Sex Med 2010;7:3045-56.
9. Druyts E, Eapen S, Wu P et al. The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysis. Syst Rev 2014;3:116.
10. Bobes J, Garcia-Portilla MP, Rejas J et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003;29:125-47.
11. Chiesa A, Leucci V, Serretti A. Antipsychotics and sexual dysfunction: epidemiology, mechanisms and management. Clin Neuropsychiatry 2013;10:31-6.
12. Uçok A, Incesu C, Aker T et al. Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur Psychiatry 2007;22:328-33.
13. Montejo AL, Majadas S, Rico-Villademoros F et al. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sex Med 2010;7:3404-13.
14. Sathish Kumar SV, Sinha VK. Comparative study of sexual dysfunction and serum prolactin level associated with olanzapine, risperidone, and clozapine in patients with remitted schizophrenia. Indian J Psychiatry 2015;57:386-91.
15. Malik P, Kemmler G, Hummer M et al. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol 2011;31:274-80.
16. Weiden PJ, Miller AL. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications.
J Psychiatr Pract 2001;7:41-7.
17. Olfson M, Uttaro T, Carson WH et al. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry 2005;66:331-8.
18. de Boer MK, Castelein S, Wiersma D et al. The facts about sexual (dys)- function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull 2015;41:674-86.
19. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64:2291-314.
20. Besnard I, Auclair V, Callery G et al. Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance. Encephale 2014;40:86-94.
21. Knegtering R, Castelein S, Bous H et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 2004;24:56-61.
22. Knegtering H, Boks M, Blijd C et al. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther 2006;32:315-26.
23. Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 2011;26:130-40.
24. Potkin SG, Loze JY, Forray C et al. Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY. Int Clin Psychopharmacol 2017;32:147-54.
25. Montes de Oca P, Macotela Y, Nava G et al. Prolactin stimulates integrinmediated adhesion of circulating mononuclear cells to endothelial cells. Lab Invest 2005;85:633-42.
26. Molinari C, Grossini E, Mary DA et al. Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology 2007;148:4080-90.
27. Rosenberg KP, Bleiberg KL, Koscis J et al. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther 2003;29:289-96.
28. Tharoor H, Kaliappan A, Gopal S. Sexual dysfunctions in schizophrenia: professionals and patients perspectives. Indian J Psychiatry 2015;57:85-7.
29. De Hert M, Detraux J, Peuskens J. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review. Expert Opin Drug Saf 2014;13:605-24.
30. de Boer MK, Castelein S, Bous J, et al. The Antipsychotics and Sexual Functioning Questionnaire (ASFQ): preliminary evidence for reliability and validity. Schizophr Res 2013;150:410-5.
31. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull 1997;33:731-45.
32. Montejo AL, Rico-Villademoros F. Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders.
J Sex Marital Ther 2008;34:227-39.
33. de Boer MK, Castelein S, Wiersma D et al. A systematic review of instruments to measure sexual functioning in patients using antipsychotics. J Sex Res 2014;51:383-9.
34. Kelly DL, Conley RR. Sexuality and schizophrenia: a review. Schi-zophr Bull 2004;30:767-79.
35. Bebbington PE, Angermeyer M, Azorin JM et al. Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand 2009;119(Suppl. 438):22-8.
36. Dibonaventura M, Gabriel S, Dupclay L et al. A patient perspective of the impact of medication side effects on adherence: results of a crosssectional nationwide survey of patients with schizophrenia. BMC Psychiatry 2012;12:20.
37. Montejo AL, Riesgo Y, Luque J et al. Observational, open-label, prospective multicenter study of sexual function in patients starting treatment with aripiprazole. Actas Esp Psiquiatr 2010;38:13-21.
38. Jeong HG, Lee MS, Lee HY et al. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study. Int Clin Psychopharmacol 2012;27:177-83.
39. Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1978-81.
40. Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychoticinduced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:714-7.
41. Meng M, Li W, Zhang S et al. Using aripiprazole to reduce antipsychoticinduced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Arch Psychiatry 2015;27:4-17.
42. Fujioi J, Iwamoto K, Banno M et al. Effect of adjunctive aripiprazole on sexual dysfunction in schizophrenia: a preliminary open-label study. Pharmacopsychiatry 2017;50:74-8.
43. Montejo González AL, Rico-Villademoros F, Tafalla M et al.
A 6-month prospective observational study on the effects of quetiapine on sexual functioning. J Clin Psychopharmacol 2005;25:533-8.
44. Montejo AL, Rico-Villademoros F, Daniel E et al. Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month, prospective, observational study. J Clin Psychopharmacol 2008;28:568-70.
45. Schmidt HM, Hagen M, Kriston L et al. Management of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database Syst Rev 2012;11:CD003546.
46. Montejo ÁL, Arango C, Bernardo M et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol 2017;45:25-34.
47. Basson R, Rees P, Wang R et al. Sexual function in chronic illness.
J Sex Med 2010;7:374-88.
48. Nicolosi A, Laumann EO, Glasser DB et al. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology 2004;64:991-7.
49. Atlantis E, Sullivan T. Bidirectional association between depression and sexual dysfunction: a systematic review and meta-analysis. J Sex Med 2012;9:1497-507.
50. Angst J. Sexual problems in healthy and depressed persons. Int Clin Psychopharmacol 1998;13:S1-4.
51. Cyranowski JM, Bromberger J, Youk A et al. Lifetime depression history and sexual function in women at midlife. Arch Sex Behav 2004;33:539-48.
52. Vanwesenbeeck I, Have MT, de Graaf R. Associations between common mental disorders and sexual dissatisfaction in the general population. Br J Psychiatry 2014;205:151-7.
53. Hegeman JM, Kok RM, van der Mast RC et al. Phenomenology of depression in older compared with younger adults: meta-analysis. Br J Psychiatry 2012;200:275-81.
54. Lin C-F, Juang Y-Y, Wen J-K et al. Correlations between sexual dysfunction, depression, anxiety, and somatic symptoms among patients with major depressive disorder. Chang Gung Med J 2012;35:323-31.
55. Laurent SM, Simons AD. Sexual dysfunction in depression and anxiety: conceptualizing sexual dysfunction as part of an internalizing dimension. Clin Psychol Rev 2009;29:573-85.
56. Vulink NCC, Denys D, Bus L et al. Sexual pleasure in women with obsessivecompulsive disorder? J Affect Disord 2006;91:19-25.
57. Aksaray G, Yelken B, Kaptanoglu C et al. Sexuality in women with obsessive compulsive disorder. J Sex Marital Ther 2001;27:273-7.
58. Williams K, Reynolds MF. Sexual dysfunction in major depression. CNS Spectr 2006;11:19-23.
59. Nazareth I, Boynton P, King M. Problems with sexual function in people attending London general practitioners: cross sectional study. BMJ 2003; 327:423-6.
60. Read S, King M, Watson J. Sexual dysfunction in primary medical care: prevalence, characteristics and detection by the general practitioner. J Publ Health Med 1997;19:387-91.
61. Rief W, Nestoriuc Y, von Lilienfeld-Toal A et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf 2009;32:1041-56.
62. Haberfellner EM. A review of the assessment of antidepressant-induced sexual dysfunction used in randomized, controlled clinical trials. Pharmacopsychiatry 2007;40:173-82.
63. McGahuey CA, Gelenberg AJ, Laukes CA et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25- 40.
64. Kennedy SH, Rizvi SJ, Fulton K et al. The Sex Effects Scale: pilot validation in a healthy population. Psychopharmacol Bull 2010;43:15-25.
65. Williams VSL, Baldwin DS, Hogue SL et al. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. J Clin Psychiatry 2006;67:204-10.
66. Williams VSL, Edin HM, Hogue SL et al. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol 2010;24:489-96.
67. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009;29: 259-66.
68. Gartlehner G, Hansen RA, Morgan LC et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 2011;155:772- 85.
69. Demyttenaere K, Jaspers L. Bupropion and SSRI-induced side effects. J Psychopharmacol 2008;22:792-804.
70. Reichenpfader U, Gartlehner G, Morgan LC et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf 2014;37:19-31.
71. Watanabe N, Omori IM, Nakagawa A et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev 2011;12: CD006528.
72. Benelli A, Frigeri C, Bertolini A et al. Influence of mirtazapine on the sexual behavior of male rats. Psychopharmacology 2004;171:250-8.
73. Montejo A, Majadas S, Rizvi SJ et al. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol 2011;26:537-42.
74. Montejo AL, Prieto N, Terleira A et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQSALSEX scale. J Psychopharmacol 2010;24:111-20.
75. Kennedy SH, Rizvi S, Fulton K et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28:329-33.
76. Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011;378:621-31.
77. Montejo AL, Deakin JF, Gaillard R et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale. J Psychopharmacol 2015;29:1119-28.
78. Gocmez S, Utkan T, Gacar N. Chronic administration of imipramine but not agomelatine and moclobemide affects the nitrergic relaxation of rabbit corpus cavernosum smooth muscle. Eur J Pharmacol 2013;714:442-7.
79. Schwartz TL, Siddiqui UA, Stahl SM. Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. Ther Adv Psychopharmacol 2011;1:81-7.
80. Clayton AH, Kennedy SH, Edwards JB et al. The effect of vilazodone on sexual function during the treatment of major depressive disorder.
J Sex Med 2013;10:2465-76.
81. Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2012;66:356-68.
82. Baldwin DS, Hanumanthaiah VB. Vortioxetine in the treatment of major depressive disorder. Future Neurol (in press).
83. Zourkova AEH. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects. Gen Physiol Biophys 2003;22:103-13.
84. Zourkova A, Ceskova E, Hadasova E et al. Links among paroxetineinduced sexual dysfunctions, gender, and CYP2D6 activity. J Sex Marital Ther 2007;33:343-55.
85. Zourkova A, Slanar O, Jarkovsky J et al. MDR1 in paroxetine-induced sexual dysfunction. J Sex Marital Ther 2013;39:71-8.
86. Waldinger MD. Premature ejaculation: state of the art. Urol Clin North Am 2007;34:591-9.
87. Giuliano F, Hellstrom WJG. The pharmacological treatment of premature ejaculation. BJU Int 2008;102:668-75.
88. Hutchinson K, Cruickshank K, Wylie K. A benefit-risk assessment of dapoxetine in the treatment of premature ejaculation. Drug Saf 2012;35:359-72.
89. Jern P, Johansson A, Piha J et al. Antidepressant treatment of premature ejaculation: discontinuation rates and prevalence of side effects for dapoxetine and paroxetine in a naturalistic setting. Int J Impot Res 2015;27:75-80.
90. Fink HA, Macdonald R, Rutks IR et al. Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU Int 2003;92:441-6.
91. Baldwin D, Bridgman K, Buis C. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. J Psychopharmacol 2006;20:91-6.
92. Baldwin D, More RA, Brlley M. Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Hum Psychopharmacol 2008;23:527-32.
93. Clayton AH, Reddy S, Focht K et al. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo. J Sex Med 2013;10:768-76.
94. Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction. Acta Psychiatr Scand 2006;114:384-97.
95. Crawford AA, Lewis S, Nutt D et al. Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Psychopharmacology 2014;231:2921-31.
96. Hu XH, Bull SA, Hunkeler EM et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004;65:959-65.
97. Taylor MJ, Rudkin L, Hawton K. Strategies for managing antidepressantinduced sexual dysfunction: systematic review of randomised controlled trials. J Affect Disord 2005;88:241-54.
98. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006;67(Suppl. 6):33-7.
99. Baldwin DS, Palazzo MC, Masdrakis VG. Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants. Depress Res Treat 2013;2013:256841.
100. Balon R, Segraves RT. Survey of treatment practices for sexual dysfunction(s) associated with anti-depressants. J SexMarital Ther 2008;34:353-65.
101. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry 1995;152:1514-6.
102. Baldwin DS. Sexual dysfunction associated with antidepressant drugs. Expert Opin Drug Saf 2004;3:457-70.
103. Amiaz R, Pope HG Jr, Mahne T et al. Testosterone gel replacement improves sexual function in depressed men taking serotonergic antidepressants: a randomized, placebo-controlled clinical trial. J Sex Marital Ther 2011;37:243-54.
104. Nurnberg HG, Hensley PL, Gelenberg AJ et al. Treatment of antidepressantassociated sexual dysfunction with sildenafil – A randomized controlled trial. JAMA 2003;289:56-64.
105. Nurnberg HG, Hensley PL, Heiman JR et al. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA 2008;300:395-404.
106. Segraves RT, Lee J, Stevenson R et al. Tadalafil for treatment of erectile dysfunction in men on antidepressants. J Clin Psychopharmacol 2007;27: 62-6.
107. Michelson D, Kociban K, Tamura R et al. Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial.
J Psychiatr Res 2002;36:147-52.
108. Fava M, Dording CM, Baker RA et al. Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. Prim Care Companion CNS Disord 2011;13:PCC.10m00994.
109. Lorenz TA, Meston CM. Exercise improves sexual function in women taking antidepressants: results from a randomised crossover trial. Depress Anxiety 2014;31:188-95.
110. Andersson KE. Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev 2011;63:811-59.
111. Musicki B, Liu T, Lagoda GA et al. Endothelial nitric oxide synthase regulation in female genital tract structures. J Sex Med 2009;6:247-53.
112. Nurnberg HG, Seidman SN, Gelenberg AJ et al. Depression, antidepressant therapies, and erectile dysfunction: Clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. Urology 2002;60:58-66.
113. Rosen RC, Seidman SN, Menza MA et al. Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms. Int J Impot Res 2004;16:334-40.
114. Kennedy SH, Dugre H, Defoy I. A multicenter, double-blind, placebocontrolled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder. Int Clin Psychopharmacol 2011;26:151-8.
115. Wegener G, Harvey BH, Bonefeld B et al. Increased stress-evoked nitric oxide signalling in the Flinders sensitive line (FSL) rat: a genetic animal model of depression. Int J Neuropsychopharmacol 2010;13:461-73.
116. Liebenberg N, Harvey BH, Brand L et al. Chronic treatment with the phosphodiesterase type 5 inhibitors sildenafil and tadalafil display anxiolytic effects in Flinders Sensitive Line rats. Metab Brain Dis 2012;27:337-40.
117. Brink CB, Clapton JD, Eagar BE et al. Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies. J Neural Transm 2008;115:117-25.
118. Kopeykina I, Kim H-J, Khatun T et al. Hypersexuality and couple relationships in bipolar disorder: a review. J Affect Disord 2016;195:1-14.
119. Mazza M, Harnic D, Catalano V et al. Sexual behavior in women with bipolar disorder. J Affect Disord 2011;131:364-7.
120. Raja M, Azzoni A. Sexual behavior and sexual problems among patients with severe chronic psychoses. Eur Psychiatry 2003;18:70-6.
121. Downey J, Friedman RC, Haase E et al. Comparison of sexual experience and behavior between bipolar outpatients and outpatients without mood disorders. Psychiatry J 2016;2016:5839181.
122. Samalin L, de Chazeron I, Vieta E et al. Residual symptoms and specific functional impairments in euthymic patients with bipolar disorder. Bipolar Disord 2016;18:164-73.
123. Dell’Osso L, Carmassi C, Carlini M et al. Sexual dysfunctions and suicidality in patients with bipolar disorder and unipolar depression. J Sex Med 2009;6:3063-70.
124. Grover S, Ghosh A, Sarkar S et al. Sexual dysfunction in clinically stable patients with bipolar disorder receiving lithium. J Clin Psychopharmacol 2014;34:475-82.
125. Chen LP, Murad MH, Paras ML et al. Sexual abuse and lifetime diagnosis of psychiatric disorders: systematic review and meta-analysis. Mayo Clin Proc 2010;85:618-29.
126. Romero S, Birmaher B, Axelson D et al. Prevalence and correlates of physical and sexual abuse in children and adolescents with bipolar disorder. J Affect Disord 2009;112:144-50.
127. Fountoulakis KN, Kasper S, Andreassen O et al. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 2012;262:1-48.
128. Elnazer HY, Sampson A, Baldwin D. Lithium and sexual dysfunction: an under-researched area. Hum Psychopharmacol Clin Exp 2015;30:66-9.
129. Zuncheddu C, Carpiniello B. Sexual dysfunctions and bipolar disorder: a study of patients submitted to a long-term lithium treatment. Clin Ter 2006;157:419-24.
130. Dols A, Sienaert P, van Gerven H et al. The prevalence and management of side effects of lithium and anticonvulsants as mood stabilizers in bipolar disorder from a clinical perspective. Int Clin Psychopharmacol 2013;28:287-96.
131. Kesebir S, Toprak B, Baykaran B et al. The level of awareness on sexually transmitted diseases of patients with bipolar mood disorder and patients with heroine dependence. Nöoro Psikiyatr Arşivi 2014;51:242-7.
132. Ghadirian AM, Ananble L, Belanger MC. Lithium, benzodiazepines, and sexual function in bipolar patients. Am J Psychiatry 1992;149:801-5.
133. Kuba R, Pohanka M, Zákopcan J et al. Sexual dysfunctions and blood hormonal profile in men with focal epilepsy. Epilepsia 2006;47:2135-40.
134. Herzog AG, Drislane FW, Schomer D et al. Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy. Neurology 2005;65:1016-20.
135. Szupera Z. The role of the antiepileptic drugs at the development of the sexual dysfunctions in male epileptic patients. Ideggyogy Sz 2007;60:4-13.
136. Yang Y, Wang X. Sexual dysfunction related to antiepileptic drugs in patients with epilepsy. Expert Opin Drug Saf 2016;15:31-42.
137. Pacchiarotti I, Murru A, Kotzalidis GD et al. Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice. Eur Neuropsychopharmacol 2015;25:1045-59.
138. La Torre A, Giupponi G, Duffy D et al. Sexual dysfunction related to psychotropic drugs: a critical review. Part III: mood stabilizers and anxiolytic drugs. Pharmacopsychiatry 2014;47:1-6.
139. Verrotti A, D’Egidio C, Mohn A et al. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 2011;52:199-211.
140. Schneck CD, Thomas MR, Gundersen D. Sexual side effects associated with valproate. J Clin Psychopharmacol 2002;22:532-4.
141. Verrotti A, Mencaroni E, Cofini M et al. Valproic acid metabolism and its consequences on sexual functions. Curr Drug Metab 2016;17:573-81.
142. Murru A, Popovic D, Pacchiarotti I et al. Management of adverse effects of mood stabilizers. Curr Psychiatry Rep 2015;17:66.
143. Pavone C, Giacalone N, Vella M et al. Relation between sexual dysfunctions and epilepsy, type of epilepsy, type of antiepileptic drugs: a prospective study. Urologia 2017;84:88-92.
144. Boora K, Chiappone K, Dubovsky SL. Oxcarbazepine-induced reversible anorgasmia and ejaculatory failure: a case report. Prim Care Companion J Clin Psychiatry 2009;11:173-4.
145. Calabró RS, Italiano D, Pollicino P et al. Oxcarbazepine-related retrograde ejaculation. Epilepsy Behav 2012;25:174-5.
146. Harden CL. Sexual dysfunction in women with epilepsy. Seizure 2008;17:131-5.
147. Bowden CL, Asnis GM, Ginsberg LD et al. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004;27:173-84.
148. Yogarajah M, Mula M. Sexual dysfunction in epilepsy and the role of anti-epileptic drugs. Curr Pharm Des (in press).
149. Saroukhani S, Emami-Parsa M, Modabbernia A et al. Aspirin for treatment of lithium-associated sexual dysfunction in men: randomized double-blind placebo-controlled study. Bipolar Disord 2013;15:650-6.
150. Gil-Nagel A, López-Muñoz F, Serratosa JM et al. Effect of lamotrigine on sexual function in patients with epilepsy. Seizure 2006;15:142-9.
151. Husain AM, Carwille ST, Miller PP et al. Improved sexual function in three men taking lamotrigine for epilepsy. South Med J 2000;93:335-6.